Horizon Therapeutics Plc - Company Profile
Powered by 
All the data and insights you need on Horizon Therapeutics Plc in one report.
$295
- Save hours of research time and resources with
our up-to-date Horizon Therapeutics Plc Strategy Report
- Understand Horizon Therapeutics Plc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Horizon Therapeutics Plc (Horizon Therapeutics) formerly Horizon Pharma plc, is a pharmaceutical company, which develops and commercializes medical products for the treatment of rare, autoimmune, arthritis and severe inflammatory diseases. It markets medicines through its orphan, primary care and rheumatology business units. A few of the company’s marketed products include Actimmune, Buphenyl, Duexis, Krystexxa, Pennsaid, Procysbi, Quinsair, Ravicti, Rayos, Uplinza, Tepezza and Vimovo. Horizon Therapeutics provides products and services to patients and healthcare professionals in the US. The company operates through offices in the US, Switzerland, Luxembourg, Bermuda, Germany, Canada, and Israel. Horizon Therapeutics is headquartered in Dublin, Ireland.
Headquarters
Ireland
Address
70 St. Stephen's Green, Saint Kevin's, Dublin 2, D02E2X4
Website
www.horizontherapeutics.com
Telephone
353 1 7722100
No of Employees
2,190
Industry
Pharmaceuticals and Healthcare
Revenue (2022)
$3.6B
Horizon Therapeutics Plc premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Rayos | Tepezza |
| Vimovo | Actimmune |
| Pipeline | Buphenyl |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2023 | Ownership Changes | In October, the company was acquired by Amgen Inc for US$27.8 billion. |
| 2023 | Contracts/Agreements | In September, the company and Q32 Bio announced a collaboration to develop bempikibart. |
| 2023 | Regulatory Approval | In June, the company announced the Brazilian Health Regulatory Agency (ANVISA) approved TEPEZZA for the treatment of active TED. |
Competitor Comparison
| Key Parameters | Horizon Therapeutics Plc | Acorda Therapeutics Inc | Spyre Therapeutics Inc | Sucampo Pharmaceuticals Inc |
|---|---|---|---|---|
| Headquarters | Ireland | United States of America | United States of America | United States of America |
| City | Dublin | Pearl River | Waltham | Rockville |
| State/Province | - | New York | Massachusetts | Maryland |
| No. of Employees | 2,190 | 102 | 30 | - |
| Entity Type | Private | Public | Public | Private |
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Timothy P. Walbert | Chief Executive Officer; President; Chairman | Executive Board | 2010 | 56 |
| Aaron Cox | Executive Vice President; Chief Financial Officer | Senior Management | 2022 | 40 |
| Andy Pasternak | Chief Strategy Officer; Executive Vice President | Senior Management | 2019 | 52 |
| Geoffrey M. Curtis | Chief Communications Officer; Executive Vice President - Corporate Affairs | Senior Management | 2018 | 49 |
| Irina Konstantinovsky | Executive Vice President; Chief Diversity Officer; Chief Human Resources Officer | Senior Management | 2020 | 53 |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward